Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic
ورودیهای بالینی بیمار
حداقل ۰ — حداکثر ۲۵ • واحد: g/dL
حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: cells/mm³
حداقل ۰ — حداکثر ۲۰۰۰۰۰۰ • واحد: cells/mm³
حداقل ۰ — حداکثر ۵۰۰۰۰۰ • واحد: cells/mm³
حداقل ۰ — حداکثر ۵۰۰۰۰ • واحد: cells/mm³
حداقل ۳۰ — حداکثر ۴۵ • واحد: °C
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Grade 00–0
- Grade 11–1
- Grade 22–2
- Grade 33–3
The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic calculator is designed for bedside assessing anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic antineoplastic.
Clinical Guidelines & Evidence
Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.
Clinical Indication
The Common Terminology Criteria for Adverse Events (CTCAE) v5.0 - Hematologic is indicated for bedside clinical practice to support Grades severity of hematologic and lymphatic adverse events from cancer treatment using standardized criteria. Assesses anemia, neutropenia, thrombocytopenia, and other blood disorders according to laboratory values and clinical presentations.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
Grade assignment based on laboratory values compared to standardized thresholds for each adverse event type according to CTCAE v5.0 criteria
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| adverse_event_type | string | Yes | Type of hematologic adverse event to grade |
| hemoglobin | float | No | Hemoglobin level (g/dL) - required for anemia grading(g/dL) |
| neutrophil_count | float | No | Absolute neutrophil count (ANC) in cells/mm³ or x10⁹/L - required for neutropenia/febrile neutropenia grading(cells/mm³) |
| platelet_count | float | No | Platelet count in cells/mm³ or x10⁹/L - required for thrombocytopenia grading(cells/mm³) |
| wbc_count | float | No | White blood cell count in cells/mm³ or x10⁹/L - required for leukocytosis grading(cells/mm³) |
| lymphocyte_count | float | No | Absolute lymphocyte count in cells/mm³ or x10⁹/L - required for lymphopenia grading(cells/mm³) |
| temperature | float | No | Body temperature in Celsius - required for febrile neutropenia grading(°C) |
| patient_sex | string | Yes | Patient biological sex for determining normal ranges |
| transfusion_indicated | string | No | Whether transfusion is clinically indicated - helps determine anemia grade 3 |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Grade 0 | Within normal limits |
| 1–1 | Grade 1 | Mild adverse event |
| 2–2 | Grade 2 | Moderate adverse event |
| 3–3 | Grade 3 | Severe adverse event |
| 4–4 | Grade 4 | Life-threatening adverse event |
| 5–5 | Grade 5 | Death |
Evidence-Based References (EBM)
- National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
- Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021 Feb;112(2):90-92.
- Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106(9):dju244.